Nasdaq:RZLT

Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET  REDWOOD CITY, Calif., June…

<!-- Name:DistributionId Value:8794674 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8783849 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at…

Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug…

Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:…

Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal antibody in Phase 2b development, has normalized blood…